Trial Profile
Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Olanzapine (Primary) ; Aprepitant
- Indications Nausea and vomiting
- Focus Therapeutic Use
- 20 Dec 2022 Status changed from recruiting to completed.
- 24 Jan 2019 Planned number of patients changed from 370 to 429.
- 24 Jan 2019 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.